In AITL patients, the only individual mutation which confers a significant inferior survival was IDH2. The adverse impact of TET2, RHOA, and DNMT3A mutations in AITL reported by other groups [2, 8] were not observed in our study. This evidence concerns the gene TET2 and angioimmunoblastic T-cell lymphoma.